Chronic kidney disease prevalence and risk factors among HIV-infected patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 4, 2008, Pages 509-510

  Sorlí, María L ^a   Guelar, Ana ^a   Montero, Milagro ^a   González, Alicia ^a   Rodriguez, Eva ^a   Knobel, Hernando ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TENOFOVIR;

BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LETTER; LIPOATROPHY; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; SEX DIFFERENCE; ADULT; CHRONIC DISEASE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; KIDNEY DISEASE; MALE; RISK FACTOR; SPAIN;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; MALE; PREVALENCE; RISK FACTORS; SEX FACTORS; SPAIN;

EID: 66749120096     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31817bbecb     Document Type: Letter

References (9)

1. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev. 1995;8:515-548.
2. Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res. 2007;5:355-360.
3. Inverarity D, Bradshaw Q, Wright P, et al. The spectrum of HIV-related disease in rural Central Thailand. Southeast Asian J Trop Med Public Health. 2002;33:822-831.
4. Tansuphasawadikul S, Amornkul PN, Tanchanpong C, et al. Clinical presentation of hospitalized adult patients with HIV infection and AIDS in Bangkok, Thailand. J Acquir Immune Defic Syndr. 1999;21:326-332.
5. Ruxrungtham K, Phanuphak P. Update on HIV/AIDS in Thailand. J Med Assoc Thai. 2001;84(Suppl 1):S1-S17.
6. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:710-718.
7. Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization (WHO). Scaling up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. 2006 Revision. Geneva. Switzerland: World Health Organization; 2006.
8. US Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October, 2006. Available at: http://AIDSinfo. nih.gov. Accessed October 11, 2007.
9. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119- 129.